Table 2.
Patient baseline characteristics
| Characteristics | Number | % |
| Total patients | 100 | 100 |
| Age (years) | ||
| Median | 65 | |
| IQR | 54–72 | |
| Sex | ||
| Male | 39 | 39 |
| Female | 61 | 61 |
| Tumor type | ||
| Biliary tract | 1 | 1 |
| Brain | 8 | 8 |
| Carcinoma of unknown primary | 0 | 0 |
| Colon | 33 | 33 |
| Duodenum | 0 | 0 |
| Endometrial | 29 | 29 |
| Oesophagus | 2 | 2 |
| Gall bladder | 1 | 1 |
| Gastric | 8 | 8 |
| Head | 1 | 1 |
| Lung | 1 | 1 |
| Ovarian | 3 | 3 |
| Pancreas | 2 | 2 |
| Prostate | 3 | 3 |
| Small intestine | 5 | 5 |
| Surreal gland | 1 | 1 |
| Urothelial | 1 | 1 |
| Uterine cervix | 1 | 1 |
| RMH score | ||
| Median | 2 | |
| IQR | 1–2 | |
| Treatment | ||
| Anti-PD-1 | 59 | 59 |
| Anti-PD-L1 | 41 | 41 |
| Tumor burden (RECIST V.1.1) | ||
| Median | 53 | |
| IQR | 29–81 | |
| Responder to ICB treatment* | ||
| Yes | 42 | 42 |
| No | 58 | 58 |
*A patient is considered as a responder if the best response during treatment was either partial or complete. Stable disease patients were considered non-responders.
ICB, immune checkpoint blockade; PD-1, programmed death 1; PD-L1, programmed death ligand 1; RMH, Royal Marsden Hospital Prognostic.